Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC
Bullboard Posts
User Avatar Image
(0)
•••
Post by toothpickon Aug 19, 2010 5:30pm
403 Views
Post# 17367008

Wall Street Journal

Wall Street Journal
https://online.wsj.com/article/BT-CO-20100819-709674.html

AUGUST 19, 2010, 2:00 P.M. ET

Canada Hot Stocks: Open Text, Aecon, Minefinders
(...)
Bioniche (C$1.07, C
.08, 8.1%) and its development partner are preparing to initiate a large study with Urocidin in the second half of 2010 that Bioniche said "could become the pivotal study" of Urocidin, which is aimed at treating bladder cancer.
(...)

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities